FDA grants accelerated approval to Rybrevant Faspro for advanced head and neck cancer after chemo and immunotherapy. In the OrigAMI-4 trial, 42% of patients saw their tumors shrink or disappear. hubs.li/Q04DBs8c0
CURE Today
This account is verified because it's an official organization on X. Learn more@cure_today
Cancer updates, research and education for patients with cancer, survivors and their caregivers to become empowered advocates in their journey.
2.1K Following 25K Followers 33K Posts
Latest posts 5
🎃 Carve out time for gratitude this Halloween. Nominate the oncology nurse who lit the way for you or your loved one for the 2027. Deadline: Dec. 9. hubs.li/Q04CVp5Z0
#ExtraordinaryHealer #OncologyNursing #Halloween #Gratitude
#ExtraordinaryHealer #OncologyNursing #Halloween #Gratitude
Living with or caring for someone with GI cancer? You’re not alone. Join @RueschCenter Nov 21 for Patient & Caregiver Day: survivorship, palliative care, and community.
Register: hubs.li/Q04BxQrf0
@LombardiCancer @MedStarGUH @Onclive #GICancer #CaregiverSupport
Register: hubs.li/Q04BxQrf0
@LombardiCancer @MedStarGUH @Onclive #GICancer #CaregiverSupport
FDA approves talazoparib + enzalutamide for metastatic hormone-sensitive prostate cancer with HRR gene mutations, based on TALAPRO-3 (rPFS HR 0.48; OS immature). Full story: hubs.li/Q04CkbMM0
FDA grants full approval to Keytruda for TMB-high solid tumors, but raises the cutoff to ≥13 mutations/megabase (from 10). In KEYNOTE-158, 36% of patients responded. What it means for patients: hubs.li/Q04C490d0
